Analysts Impressed As Novo Nordisk’s PIONEER 6 Trial Confirms Safety Profile Of Oral Semaglutide

Oral semaglutide hit its main endpoint by demonstrating cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in the PIONEER 6 trial.

Heart
Trial is part of Novo Nordisk's PIONEER clinical development program • Source: Shutterstock

Novo Nordisk AS’s investigational oral version of its GLP-1 agonist semaglutide is safe in patients with type 2 diabetes at high cardiovascular risk, according to full results from the PIONEER 6 study released at the American Diabetes Association (ADA) on 11 June, which showed a non-significant 21% reduction in major adverse cardiac events (MACE).

Full results of PIONEER 6, topline data from which was released last November, showed the trial met the primary objective of demonstrating non-inferiority to placebo in the incidence of major...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Alimentary/Metabolic

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By 

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Multiple Launches Help Lilly’s Japan Growth

 
• By 

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

More from Therapy Areas

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.

End Is Nigh For 4SC After EMA’s No For Kinselby

 
• By 

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.